EP300 and cancer: Although the development of small-molecule CBP/p300 histone acetyltransferase inhibitors has sparked broad interest with regard to cancer treatment, inhibiting a single domain of one of these targets cannot completely ablate its function, as p300/CBP is comprised of eight discrete functional domains 132.